Biomea Fusion Inc.

BMEA | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.75

+$0.04 (+2.34%)

Sep 22, 2026, 2:32 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.34%

(1D)

Rating

Updated: Aug 27, 2026

24.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $126.89M

1D Range

1.66 1.78

52W Range

0.87 2.99

Valuation (TTM)

PE -3.42

PB 10.19

EV/EBITDA -2.62

Valuation (NTM)

Forward PE N/A

Forward PEG -0.11

Price Target $20.20

Cash Flow

FCF Yield -38.1%

SBC Adj. FCF Yield -40.6%

SBC Impact -6.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 68.6% | 13.5%

FCF 3Y | 5Y 37.4% | 0.3%

Returns

ROA -88.2%

ROE -171.2%

ROIC -212.9%

Financial Health

Net Cash

$33.95M

Current Ratio 3.47

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical pro...

Sector Healthcare

Industry Biotechnology

Employees 37

IPO Date Apr 15, 2021

Website biomeafusion.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$19

Upside

+985.71%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞